Nine Point Two Capital LLC Immuno Gen, Inc. Transaction History

Nine Point Two Capital LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $250,337 - $353,030	17,767 New	17,767 $281,000
Q4 2022 Feb 14, 2023	BUY	$4.55 - $6.31 $170,775 - $236,833	37,533 New	37,533 $186,000
Q2 2022 Aug 15, 2022	SELL	$3.15 - $5.76 $275,631 - $504,011	-87,502 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.26 - $7.48 $372,758 - $654,514	87,502 New	87,502 $416,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Nine Point Two Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Nine Point Two Capital LLC with notifications on news.